Market revenue in 2023 | USD 78.4 million |
Market revenue in 2030 | USD 105.5 million |
Growth rate | 4.3% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Roche Holding AG ADR, GlaxoSmithKline, Johnson & Johnson, AstraZeneca PLC, Siemens Healthineers AG ADR, Quest Diagnostics Inc, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Abbott Laboratories |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ovarian cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 61.86% in 2023. Horizon Databook has segmented the Mexico ovarian cancer diagnostics market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico ovarian cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Mexico ovarian cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account